3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Vomiting
13
Nausea
6
Neoplasms
5
Multiple Myeloma
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Melanoma
1
Gynecologic Cancer
1
Genital Neoplasms, Female
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
143
pembrolizumab
129
Sunitinib
127
Bevacizumab
71
Everolimus
70
Sorafenib
68
cabozantinib
64
Ipilimumab
61
pazopanib
58
Axitinib
57
aldesleukin
51
Magnetic Resonance Spectroscopy
43
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
36
Radiosurgery
36
Specimen Handling
33
Interferon-alpha
32
atezolizumab
29
belzutifan
24
temsirolimus
23
Gemcitabine
23
fludarabine phosphate
22
Radiotherapy
18
Interferon alpha-2
18
Biopsy
18
fludarabine
17
durvalumab
17
avelumab
17
Paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Renal Cell
×
fosaprepitant
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts